

Alkyl Amines

Supply glut in the domestic market

We maintain SELL on Alkyl Amines (AACL) with a price target of INR1,756 (WACC 12%, terminal growth 5%). Capacity addition in methylamines and its derivatives by domestic players and continued aggressive dumping by Chinese manufacturers in ethyl amines shall limit volume growth and expansion in margins. Demand in the domestic market, particularly from pharmaceuticals, was encouraging in FY24. We expect volume growth to remain below 10% YoY while product prices could increase in line with raw material prices. Investigation of anti-dumping concerning imports of acetonitrile originating from China, Russia, and Taiwan has been initiated. If the Directorate General of Trade Remedies imposes anti-dumping duty on imports from these countries, our EBITDA and APAT estimates will jump by 16/19% in FY25 and 9/11% in FY26. Softening in power and fuel costs and operating leverage will help increase the EBITDA margin. We expect EBITDA/APAT to grow at a CAGR of 19/21% over FY24-27E and RoE/RoCE to improve from 12.2/15.7% in FY24 to 11.4/14.8% in FY27. Currently, the stock is trading at 55/43.5 FY25/26.

- Domestic demand and market challenges for methylamines:** Methylamines are largely sold in the domestic market owing to challenges in exporting basic amines. Domestic demand for methylamines is more than 75ktpa and growing at a lower single-digit rate. Further, ~20-25ktpa of methylamines would be required if India started producing major derivatives (e.g. Dimethyl Formamide, N-methyl pyrrolidone etc.) which are currently being imported. In FY24, margins for the methyl chain were healthy. However, upcoming capacity additions by a competitor and one of the customers pose headwinds in the methylamines market.
- Expanding methylamines capacity:** Balaji Amines is setting up a 40mtpa methylamines (mono, di, tri) capacity which will commence production by December 2024. We believe that initially only a part of this capacity will be consumed captively to produce downstream value-added products. This will keep the prices of the methylamine value chain under control. If prices of downstream products remain benign, the probability is that the supply of methylamines will increase in the domestic market.

Financial summary

Year Ending March (Rs mn)	4Q FY24	3Q FY24	QoQ (%)	3Q FY23	YoY (%)	FY22	FY23	FY24P	FY25E	FY26E
Net Sales	3,566	3,220	10.8	4,117	(13.4)	15,420	16,823	14,406	16,998	20,581
EBITDA	689	596	15.6	769	(10.5)	3,252	3,431	2,507	3,038	3,736
APAT	385	334	15.2	486	(20.9)	2,249	2,287	1,489	1,854	2,343
Diluted EPS (Rs)	7.5	6.5	15.2	9.5	(20.9)	44.0	44.7	29.1	36.3	45.8
P/E (x)						45.3	44.6	68.5	55.0	43.5
EV / EBITDA (x)						31.2	29.9	40.5	33.1	26.7
RoE (%)						25.2	21.2	12.2	13.8	15.5

Source: Company, HSIE Research

SELL

CMP (as on 19 Jun 24)	INR2,004
Target Price	INR1,756
NIFTY	23,516

KEY CHANGES	OLD	NEW
Rating	SELL	SELL
Price Target	INR1,763	INR1,756
EPS %	FY25E -16.4%	FY26E -14.1%

KEY STOCK DATA

Bloomberg code	AACL IN
No. of Shares (mn)	51
Map (INR bn) / (\$ mn)	102/1,228
6m avg traded value (INR mn)	213
52 Week high / low	INR 2,798/1,805

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	2.2	(14.1)	(26.5)
Relative (%)	(5.2)	(22.4)	(48.9)

SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	71.96	71.96
FIs & Local MFs	1.07	1.10
FPIs	2.94	3.04
Public & Others	24.04	23.90
Pledged Shares	0.00	0.00
<i>Source : BSE</i>		

Nilesh Ghuge

nilesh.ghuge@hdfcsec.com
+91-22-6171-7342


Harshad Katkar

harshad.katkar@hdfcsec.com
+91-22-6171-7319

Prasad Vadnere

Prasad.vadnere@hdfcsec.com
+91-22-6171-7356

Exhibit-1: Process Flow chart of Metformin and Caffeine



Source: Company, HSIE Research

Aarti Drugs is planning to set up a Methylamine (mono, di and tri) and DMA-HCL plant under their backward integration project plans for Metformin and Caffeine. The plant is expected commercial operation by December 2024. Currently, Aarti Drugs is buying these key raw materials (Monomethyl amines and Di methyl amine) from the market. We believe that after the commissioning of the methyl amine facility, Aarti Drugs will sell excess production in the merchant market.

We estimate that ~60% of the existing capacities of methylamines will be added by December 2024. Intense competition for methylamines and its major derivative shall keep the margin in the methylamines market benign. In such a challenging time, the companies investing in process engineering can navigate easily.

Exhibit-2: List of companies setting up Methylamine and its derivative plants

Company	Molecule	Capacity	Stages	Commissioning month
Balaji Amines	Methylamine	to meet increasing captive requirements, The company is setting up a separate plant for Methylamines with a capacity of 40mtpa	Environmental clearance received. Project on track.	Dec-24
Aarti Drugs	Methylamine	-	-	Dec-24

Source: Company, HSIE Research

Expect capex of INR 2.2bn over FY25 and FY26

Alkyl Amines is planning to incur INR 0.6bn to INR 0.8bn on maintenance capex and some debottlenecking activity in FY25. Further, the company is planning to launch two new products. The investment decision will be taken this year. These new products will require an investment of INR0.75bn to INR2bn spread over two years. These products are not derivatives or a part of the amine portfolio. We believe that the company is looking for not only import substitution but also an export opportunity. We have factored in capex of INR 2.2bn for FY25 and FY26 and we expect this to take place through internal accruals.

Domestic Ethylamine capacity more than adequate

Domestic demand for ethylamine is ~35ktpa. Alkyl Amines has commissioned a ~30ktpa plant in Q3FY24. The company has an old plant of ~15ktpa ethylamine's at Kurkumbh. Balaji Amines has an ethylamine plant of 22.5ktpa capacity. The company has added capacity in an already oversupplied market. EBITDA per kg for Ethylamine was better in Q4FY24 compared to 9MFY24. Margins will remain healthy but the upside is limited owing to sufficient supply in the domestic market and competition from Chinese suppliers.

Change in estimates

Y/E Mar	FY25E Old	FY25E New	Change (%)	FY26E Old	FY26E New	Change (%)
EBITDA (INR mn)	3,556	3,038	-14.6	4,307	3,736	-13.3
Adj. EPS (INR/sh)	43.4	36.3	-16.4	53.3	45.8	-14.1

Source: Company, HSIE Research

Financials (Consolidated)

INCOME STATEMENT

(INR mn)	FY20	FY21	FY22	FY23	FY24P	FY25E	FY26E	FY27E
Net Revenues	9,929	12,424	15,420	16,823	14,406	16,998	20,581	23,735
Growth (%)	17.3	25.1	24.1	9.1	(14.4)	18.0	21.1	15.3
Material Expenses	4,845	5,231	8,356	8,597	7,676	9,612	12,249	14,666
Employee Expenses	696	927	881	976	952	1,028	1,110	1,176
Other Operating Expenses	1,797	1,975	2,931	3,819	3,272	3,320	3,486	3,630
EBITDA	2,590	4,291	3,252	3,431	2,507	3,038	3,736	4,263
EBITDA Margin (%)	26.1	34.5	21.1	20.4	17.4	17.9	18.2	18.0
EBITDA Growth (%)	57.6	65.7	(24.2)	5.5	(26.9)	21.2	23.0	14.1
Depreciation	269	291	348	452	589	725	784	887
EBIT	2,321	4,001	2,904	2,980	1,918	2,313	2,952	3,375
Other Income (Including EO Items)	379	70	150	139	151	163	176	191
Interest	103	63	33	33	44	1	1	1
PBT	2,597	4,007	3,021	3,086	2,025	2,475	3,128	3,565
Tax	444	1,054	772	799	536	621	785	895
RPAT	2,153	2,953	2,249	2,287	1,489	1,854	2,343	2,670
<i>Minority Interest</i>								
EO (Loss) / Profit (Net Of Tax)	355							
APAT	1,798	2,953	2,249	2,287	1,489	1,854	2,343	2,670
PAT Growth (%)	157.1	37.2	(23.9)	1.7	(34.9)	24.5	26.4	14.0
AEPS	35.2	57.8	44.0	44.7	29.1	36.3	45.8	52.2
AEPS Growth (%)	114.7	64.3	(23.9)	1.7	(34.9)	24.5	26.4	14.0

Source: Company, HSIE Research

BALANCE SHEET

(INR mn)	FY20	FY21	FY22	FY23	FY24P	FY25E	FY26E	FY27E
SOURCES OF FUNDS								
Share Capital	102	102	102	102	102	102	102	102
Reserves	5,264	7,822	9,796	11,587	12,569	14,052	15,926	17,929
Total Shareholders' Funds	5,366	7,925	9,898	11,689	12,671	14,155	16,029	18,031
Long-term Debt	479	216	-	-	-	-	-	-
Short-term Debt	0	-	227	855	6	6	6	6
Total Debt	480	216	227	855	6	6	6	6
<i>Minority Interest</i>								
Long-term Provisions & Others	47	81	64	129	149	149	149	149
Net Deferred Tax Liability	404	414	472	560	737	774	813	853
TOTAL SOURCES OF FUNDS	6,296	8,635	10,661	13,232	13,564	15,083	16,996	19,040
APPLICATION OF FUNDS								
Net Block	4,235	4,580	6,290	7,187	10,918	10,979	11,580	13,178
CWIP	449	1,376	1,426	3,525	356	370	385	400
Goodwill								
Investments	-	-	-	-	-	-	-	-
LT Loans & Advances	139	126	529	104	51	51	51	51
Other Non-Current Assets	70	91	92	97	103	108	114	120
Total Non-current Assets	4,892	6,174	8,338	10,913	11,429	11,509	12,130	13,749
Inventories	837	1,219	1,645	1,837	1,720	2,029	2,457	2,833
Debtors	1,642	2,280	2,767	2,584	2,217	2,616	3,168	3,653
Cash & Equivalents	323	1,563	626	182	314	1,427	2,254	2,341
ST Loans & Advances	2	1	2	1	1	1	1	1
Other Current Assets	138	216	336	384	182	200	220	242
Total Current Assets	2,941	5,279	5,376	4,988	4,434	6,273	8,099	9,070
Creditors	708	1,790	2,285	1,897	1,719	2,028	2,456	2,832
Other Current Liabilities	830	1,028	767	771	580	670	778	947
Total Current Liabilities	1,538	2,818	3,052	2,669	2,299	2,698	3,233	3,779
Net Current Assets	1,404	2,461	2,324	2,320	2,135	3,575	4,866	5,291
TOTAL APPLICATION OF FUNDS	6,296	8,635	10,661	13,232	13,564	15,083	16,996	19,040

Source: Company, HSIE Research

Alkyl Amines: Company Update

CASH FLOW STATEMENT

(INR mn)	FY20	FY21	FY22	FY23	FY24P	FY25E	FY26E	FY27E
Reported PBT	2,597	4,007	3,021	3,086	2,025	2,475	3,128	3,565
EO items	(355)							
Interest Expenses	103	63	33	33	44	1	1	1
Depreciation	269	291	348	452	589	725	784	887
Working Capital Change	201	183	(800)	(439)	316	(327)	(464)	(338)
Tax Paid	(547)	(1,043)	(714)	(712)	(359)	(584)	(746)	(854)
OPERATING CASH FLOW (a)	2,267	3,500	1,888	2,420	2,615	2,290	2,702	3,261
Capex	(757)	(1,564)	(2,107)	(3,448)	(1,151)	(800)	(1,400)	(2,500)
<i>Free Cash Flow (FCF)</i>	1,510	1,936	(219)	(1,028)	1,464	1,490	1,302	761
Investments	14	-	-	-	-	-	-	-
INVESTING CASH FLOW (b)	(742)	(1,564)	(2,107)	(3,448)	(1,151)	(800)	(1,400)	(2,500)
Debt Issuance/(Repaid)	(1,162)	(264)	11	628	(849)	-	-	-
Interest Expenses	(103)	(63)	(33)	(33)	(44)	(1)	(1)	(1)
<i>FCFE</i>	245	1,609	(240)	(433)	572	1,489	1,301	760
Share Capital Issuance	-	0	0	0	0	-	-	-
Dividend	(503)	(629)	(818)	(511)	(511)	(371)	(469)	(668)
Others	364	259	121	501	71	(5)	(5)	(6)
FINANCING CASH FLOW (c)	(1,404)	(696)	(718)	584	(1,333)	(377)	(475)	(674)
NET CASH FLOW (a+b+c)	121	1,240	(937)	(443)	131	1,113	827	87
EO Items, Others								
Closing Cash & Equivalents	323	1,563	626	182	314	1,427	2,254	2,341

Source: Company, HSIE Research


KEY RATIOS

	FY20	FY21	FY22	FY23	FY24P	FY25E	FY26E	FY27E
PROFITABILITY (%)								
GPM	51.2	57.9	45.8	48.9	46.7	43.5	40.5	38.2
EBITDA Margin	26.1	34.5	21.1	20.4	17.4	17.9	18.2	18.0
EBIT Margin	24.1	32.8	19.8	18.5	14.4	14.6	15.2	15.0
APAT Margin	21.7	23.8	14.6	13.6	10.3	10.9	11.4	11.3
RoE	47.8	44.4	25.2	21.2	12.2	13.8	15.5	15.7
RoIC	35.2	46.0	26.6	20.0	11.6	13.8	16.5	17.0
RoCE	37.9	40.2	23.6	19.3	11.4	12.9	14.6	14.8
EFFICIENCY								
Tax Rate (%)	17.1	26.3	25.6	25.9	26.5	25.1	25.1	25.1
Asset Turnover (x)	1.6	1.4	1.4	1.3	1.1	1.1	1.2	1.2
Inventory (days)	31	36	39	40	44	44	44	44
Debtors (days)	60	67	66	56	56	56	56	56
Other Current Assets (days)	5	6	8	8	5	4	4	4
Payables (days)	26	53	54	41	44	44	44	44
Other Current Liab & Prov (days)	3	4	4	3	4	3	3	3
Cash Conversion Cycle (days)	67	53	54	60	57	57	58	57
Net Debt/EBITDA (x)	0.1	(0.3)	(0.1)	0.2	(0.1)	(0.5)	(0.6)	(0.5)
Net D/E	0.0	(0.2)	(0.0)	0.1	(0.0)	(0.1)	(0.1)	(0.1)
Interest Coverage	23.3	64.3	93.1	93.9	47.1	4,072.0	3,910.4	4,457.3
PER SHARE DATA								
EPS (Rs/sh)	35.2	57.8	44.0	44.7	29.1	36.3	45.8	52.2
CEPS (Rs/sh)	47.4	63.5	50.8	53.6	40.7	50.5	61.2	69.6
DPS (Rs/sh)	8.0	10.0	16.0	10.0	10.0	7.3	9.2	13.1
BV (Rs/sh)	105.0	155.0	193.7	228.7	247.9	276.9	313.6	352.8
VALUATION								
P/E	56.7	34.5	45.3	44.6	68.5	55.0	43.5	38.2
P/BV	19.0	12.9	10.3	8.7	8.0	7.2	6.4	5.7
EV/EBITDA	39.4	23.4	31.2	29.9	40.5	33.1	26.7	23.4
OCF/EV (%)	2.7	3.4	1.3	2.7	2.5	2.2	2.7	3.2
FCF/EV (%)	1.9	1.9	(0.8)	(0.7)	1.3	1.4	1.3	0.7
FCFE/MCAP (%)	0.7	1.5	(0.8)	(0.1)	0.4	1.4	1.2	0.7
Dividend Yield (%)	0.4	0.5	0.8	0.5	0.5	0.4	0.5	0.7

Source: Company, HSIE Research

Alkyl Amines: Company Update

Price Movement



Rating Criteria

BUY:	>+15% return potential
ADD:	+5% to +15% return potential
REDUCE:	-10% to +5% return potential
SELL:	> 10% Downside return potential

Disclosure:

We, **Nilesh Ghuge, MMS, Harshad Katkar, MBA & Prasad Vadnere, MSc** authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in stock – No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Alkyl Amines: Company Update

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

HDFC Securities

Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park,
Senapati Bapat Marg, Lower Parel, Mumbai - 400 013
Board: +91-22-6171-7330 www.hdfcsec.com